High-Performance
RNA therapeutics
Precision engineered to power effective chronic disease management
Therapeutics
RNA therapeutics have emerged as potent tools for treating a range of diseases. Sirius is expanding the reach of RNA medicines to chronic conditions including cardiovascular, cerebrovascular, and metabolic diseases to serve the unmet medical needs of large numbers of patients.
Underpinning our high-performance RNA therapeutics is a strong understanding of the genetic basis for common diseases. Our RNA designs selectively and exquisitely leverage natural gene silencing to overcome impediments to health. Furthermore, patients will benefit from the infrequent dosing arising from the precision engineered design.
Sirius is driven to continuously innovate and optimize the potential of RNA therapeutics to transform chronic disease treatment.
Design
Sirius Therapeutics’ drugs are small RNA molecules engineered to engage with the cell’s natural gene-silencing apparatus and reduce the production of a single disease-causing protein. One dose of an RNA therapeutic exerts activity on human physiology, reduces the causative protein and alleviates disease symptoms for many months. Daily dosing of drugs for chronic illnesses is becoming a thing of the past.
We continuously discover strategies to build enhanced performance into new molecules and implement them to rapidly create more efficient, longer-lasting drugs — paving the way for lower doses and longer intervals between treatments.
Pipeline
We are engineering best-in-class medicines with superior efficacy, safety,
and convenience for patients.
Team
We are dedicated scientists, experienced clinicians, and individuals with personal stakes in
improving outcomes for patients. Every day we work to make our drugs better.
Dr. Patrick Yue, Chief Medical Officer of Sirius Therapeutics, has extensive leadership experience in clinical development including the anti-coagulant therapeutic area.
Prior to joining Sirius Therapeutics, he was the SVP of Clinical Development, Innovative Medicines at Centessa Pharmaceuticals, with oversight of multiple programs in various stages of clinical development. At Centessa，Dr. Yue oversaw the clinical development of two investigational products: SerpinPC, an activated Protein C inhibitor in Phase 2b/3 studies for the treatment of hemophilia, and ORX-750, an orexin agonist in development for the treatment of narcolepsy. He also served as a member of the executive leadership team. Prior to Centessa, Dr. Yue served at Global Blood Therapeutics, as Vice President, and Head of Clinical Science. During his tenure, he oversaw the clinical development of four products, including the marketing approval in the EU of voxelotor (OXBRYTA) for the treatment of sickle cell disease and a label expansion for pediatric use in the U.S. Previously, he led the clinical development of ANDEXXA through its approval in the US and the EU at Portola Pharmaceuticals.
Prior to joining industry, Dr. Yue completed his medical internship and residency at Beth Israel Deaconess Medical Center and received specialty training in cardiovascular medicine at Stanford University School of Medicine. Dr. Yue holds a BS in biology and chemistry from the California Institute of Technology and an MD from Washington University School of Medicine.
Dr. Curt Bradshaw, Chief Scientific Officer (CSO) of Sirius Therapeutics, is a highly-regarded pharmaceutical executive who has accumulated over 30 years of experience in drug and chemical development, including 15 years leading the development of siRNA therapeutics.
In the two decades prior to joining Sirius Therapeutics, Dr. Bradshaw had served in senior leadership positions in drug and chemistry development at multiple biotechs and large multinational pharmaceutical companies including CSO at NeuBase Therapeutics and Arrowhead Pharmaceuticals; CSO and Co-Founder at Tallac Therapeutics; CSO and Co-Founder at Solstice Biologics; and Vice President of Chemistry at the CovX Pharmaceutical unit of Pfizer.
Dr. Bradshow has a Ph.D. degree in Chemistry from Texas A&M University.
Dr. Qunsheng Ji, the Chief Executive Officer of Sirius Therapeutics, is a seasoned pharmaceutical executive with near 30-year experience in drug discovery, translational medicine, and business leadership.
Prior to Sirius Therapeutics, Dr. Ji was Vice President and Head of Oncology and Immunology Unit at WuXi AppTec. Where he led team of over 1000 R&D personnel and research business enabling drug discovery and development for hundreds of pharmaceutical and biotech companies around the world. Prior to WuXi AppTec, Dr. Ji was Head of Bioscience, Asia and Emerging Market iMed of AstraZeneca. He also served as Director of Translational Medicine, overseeing AstraZeneca’s global translational medicine portfolio.
Dr. Ji started his industry career in the U.S where he served ONYX Pharmaceuticals and OSI Pharmaceuticals, respectively.
Dr. Ji obtained his Ph.D. degrees in Cell Biology from Peking Union Medical College and Vanderbilt University in the U.S. He also received Bachelor degree of Medicine in China.
Dr. Ji is author of more than 50 peer-reviewed research articles and book chapters. In addition, he is a co-founder and vice chair of Sino Drug Discovery Association (SDDA).
Orbimed
Orbimed
David Wang, M.D., Ph.D., is a Partner and Senior Managing Director on OrbiMed Asia team, focused on Greater China.
Previously, he was a Managing Director at WI Harper Group, responsible for healthcare investments in China. He also previously served as Head of Business Development at Siemens Medical Solutions, where he directed corporate strategy and new businesses in molecular diagnostics and diagnostic imaging. Dr. Wang was a co-founder and EVP at First Genetic Trust, a personalized medicine company. During his tenure at Bristol-Myers Squibb, Dr. Wang was Chairman of The SNP Consortium Management Committee, the first group of its kind formed by pharmaceutical and technology industries to support the development of personalized medicine.
He received his M.D. from Peking University Medical School and his doctorate in Developmental Biology from the California Institute of Technology.
Dr. Qunsheng Ji is the Chief Executive Officer at Sirius Therapeutics.
Prior to Sirius, he was the Vice President and Head of the Oncology and Immunology Unit at Wuxi AppTec, and Head of BioScience and Director of Translational Medicine at Asia & Emerging Market iMed, AstraZeneca.
Dr. Qunsheng Ji holds a Doctor of Medicine (MD) degree from the First Military Medical University in China, and a Ph.D. degree in Cellular Biology from Vanderbilt University/Peking Union Medical College of the Chinese Academy of Medical Sciences.
Creacion Ventures
Creacion Ventures
Dr. Wei Li is the Founding Partner at Creacion Ventures.
Before founding Creacion Ventures, Dr. Li served as the management partner in 6 Dimensions Capital, the partner of Fidelity Biotechnology and Fidelity Growth Partners Asia, and the co-founder of Innovent.
Dr. Wei Li has successfully founded or involved in the founding of a series of biotechnology companies in China and overseas, including Innovent Biologics (stock code: 1801. HK), CStone Pharmaceuticals (stock code: 2616. HK), Ocumension Therapeutics (stock code: 1477. HK), and Dewpoint Therapeutics.
Dr. Wei Li holds a Ph.D. degree in Biochemistry from Harvard University and an MBA degree from the Northwestern University – Kellogg School of Management.
Mr. Diyong Xu is the Principal at Orbimed U.S. and former investment banking analyst at Lazard Freres & Co.
Mr. Diyong Xu holds a Master of Science (M.S.) degree in Management Science and Engineering from Stanford University, a M.S. degree in Molecular and Cellular Biology from the Dartmouth Medical School, and a Bachelor of Science degree in Biology from the Zhejiang University in China.
Mr. Kevin Yuan is the Chief Executive Officer at Shanghai Hankang Private Equity Management Co., Ltd.
Mr. Hong Yuanquan has more than 20 years of experience investing in China’s biopharmaceutical industry and has led the investment in over 40 early-stage biopharmaceutical companies, including some that already became industry leaders, such as InnoCare Pharma (9969. HK, 688428. SH), AkesoBio (9926. HK), Keymed Biosciences (2162. HK), Chipscreen Biosciences (688321. SH), Abbisko Therapeutics (2256. HK), and OPM Biosciences (688293. SH).
Mr. Kevin Yuan holds a Master degree in Management from Zhejiang University and an MBA degree from the China Europe International Business School (CEIBS).
Dr. Douglas Fambrough was the Founder, President and Chief Executive Officer of Dicerna Pharmaceuticals (a company that was acquired by Novo Nordisk for US$3.3 billion).
Dr. Douglas Fambrough holds a Ph.D. degree in Genetics from the University of California, Berkley, and a Bachelor degree in Biology from Cornell University.
